Evidence map›Paper›PMID 42133816›Full record

ArticleCardiovascular research2026

Machine learning-guided risk stratification for long QT syndrome genetic variants with hiPSC-derived cardiomyocytes.

Aleksandr Khudiakov, Manuela Mura, Federica Giannetti, Vladislav Leonov, Chiara Alberio, Marem Eskandr, Paola Adele Lonati, Maria Orietta Borghi, Paul A Brink, Lia Crotti and 3 more

Abstract read
In one paragraph

Article in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Aleksandr KhudiakovCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.ORCID 0000-0001-9214-0868
Manuela MuraTranslational Cardiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Federica GiannettiCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.ORCID 0000-0002-1785-5529
Vladislav LeonovCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Chiara AlberioCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.ORCID 0000-0002-4727-0994
Marem EskandrCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Paola Adele LonatiLaboratory of ImmunoRheumatologic Researches, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Maria Orietta BorghiLaboratory of ImmunoRheumatologic Researches, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Paul A BrinkDepartment of Medicine, University of Stellenbosch, Tygerberg, South Africa.
Lia CrottiCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Massimiliano GnecchiTranslational Cardiology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Peter J SchwartzCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.
Luca SalaCenter for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Istituto Auxologico Italiano IRCCS, Milan, Italy.ORCID 0000-0002-4129-6632

Funding

Education and ResearchFondazione CARIPLO 2019-1691From Research to BusinessHorizon 2020 795209Horizon 2020 H2020-MSCA-IF-2017Horizon Europe EU 101105561Horizon Europe EU HORIZON-MSCA-2022-PF-01Italian Ministry of University and Research within Mission 4Leducq Foundation 18CVD05National Recovery and Resilience Plan 2022-NAZ-0485National Recovery and Resilience Plan H45E22001210006young researchers
6 · The paper itself

Abstract

aimsLong QT syndrome (LQTS) is a life-threatening genetic disorder characterized by prolonged QT intervals on electrocardiograms. Congenital forms are mostly associated with variants in the KCNQ1 and KCNH2 genes. Among pathogenic or likely pathogenic (P/LP) variants, some are associated with a significantly higher incidence of cardiac events compared to others. While therapies have significantly reduced mortality, some patients are unresponsive or intolerant to therapy, perpetuating their arrhythmic risk, including sudden cardiac death. Current approaches for risk stratification are insufficient, highlighting the critical need for more accurate identification and management of patients carrying high-risk genetic variants. Here, we aimed to develop a refined risk stratification model for P/LP variants by applying machine learning classification to electrophysiological data measured in patient-specific human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). METHODS AND

resultsTen patient-specific hiPSC lines, each carrying one of six pathogenic or likely pathogenic (P/LP) variants in the KCNQ1 or KCNH2 genes, along with two healthy control hiPSC lines, were differentiated into hiPSC-CMs. Electrophysiological responses from multielectrode array recordings at baseline and after application of selective ion channel blockers or pro-arrhythmic compounds were used to train a machine learning model to classify variant-specific risk levels based on in vitro electrophysiological readouts. An independent validation cohort of two additional KCNH2 hiPSC lines was used to test the model's performance in predicting single-variant risk. Our findings revealed a correlation between variant risk level, hiPSC-CM electrophysiological profiles, and drug responses. The machine learning classifier, trained on multielectrode array recordings, achieved 89% accuracy in the classification of P/LP genetic variants according to the associated risk levels.

conclusionThis study demonstrates that integrating hiPSC-CM electrophysiological profiling with machine learning provides a robust method for granular variant-specific risk stratification of LQTS patients.

Indexed as

Action PotentialsERG1 Potassium ChannelGenetic VariationHeart RateInduced Pluripotent Stem CellsKCNQ1 Potassium ChannelLong QT SyndromeMachine LearningMutationMyocytes, CardiacPatient-Specific ModelingGenetic Predisposition to DiseaseHumansPhenotypePredictive Learning ModelsPredictive Value of TestsERG1 Potassium ChannelKCNH2 protein, humanKCNQ1 Potassium ChannelKCNQ1 protein, humanHuman-induced pluripotent stem cell-derived cardiomyocytesLong QT syndromeMachine learningPrecision medicinePro-arrhythmic drugs

Identifiers

PMID42133816
PMCPMC13355840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.